Stephanie Herndon
Acute Care · Richmond, VANPI 1992797476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 419 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.1% of the total. Among acute care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$977
- Johnson & Johnson$692
- Sanofi$673
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$589
- QOL Medical, LLC$402
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $2,090 |
| Takeda Pharmaceuticals U.S.A., Inc. | 62 | $977 |
| Johnson & Johnson | 31 | $692 |
| Sanofi | 24 | $673 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $589 |
| QOL Medical, LLC | 15 | $402 |
| Daiichi Sankyo Inc. | 9 | $322 |
| Gilead | 15 | $315 |
| Phathom Pharmaceuticals, Inc. | 15 | $311 |
| Ardelyx, Inc. | 16 | $276 |
| Intercept Pharmaceuticals, Inc. | 8 | $187 |
| Bristol Myers Squibb | 11 | $178 |
| Madrigal Pharmaceuticals | 6 | $170 |
| Pfizer | 7 | $140 |
| Ipsen Biopharmaceuticals, Inc | 5 | $133 |
| Ironwood Pharmaceuticals, Inc | 5 | $105 |
| Sandoz | 4 | $104 |
| Nestle Healthcare Nutrition Inc. | 6 | $96 |
| Organon | 7 | $92 |
| Vivus LLC | 5 | $86 |
| Enterra Medical, Inc. | 1 | $85 |
| Aimmune Therapeutics, Inc. | 3 | $74 |
| Lilly USA, LLC | 3 | $69 |
| AstraZeneca | 3 | $68 |
| Ferring Pharmaceuticals Inc. | 3 | $61 |
| Intra-sana Laboratories | 3 | $50 |
| Novo Nordisk | 2 | $46 |
| Braintree Laboratories, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| Amgen | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $23 |
| American Regent | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Curium US LLC | 1 | $20 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$125
How this compares
$8,669 in reported general payments places this provider in the 95th percentile of 599 acute care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $60,229 |
| LinzessLinaclotide | 56 | $30,867 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 103 | $6,515 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 23 | $3,880 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 21 | $3,172 |
| Colestipol Hcl | 33 | $2,065 |
| Omeprazole | 165 | $1,640 |
| Esomeprazole Magnesium | 22 | $1,255 |
| Dicyclomine Hcl | 38 | $1,133 |
| Pantoprazole Sodium | 59 | $910 |
| Famotidine | 79 | $702 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 38 | $604 |
| Ondansetron OdtOndansetron | 42 | $603 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $229 |
| Metoclopramide Hcl | 22 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,090 | $91,09778 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $61 | $3,88023 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $589 | $3,17221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 acute care providers in Virginia.
Other acute care in Richmond
- Rachel DukeRichmond$751K
- Mica FerlisRichmond$20K
- Jonathan PenderRichmond$13K
- Erin PerlmutterRichmond$13K
- Emily GilbertRichmond$10K
- Linda HazelgrenRichmond$9K
- Christine RobinsonRichmond$8K
- Kelly McAdamsRichmond$7K
- Linda KashiwabaraRichmond$7K
- Renee TierneyRichmond$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.